The FDA tentatively approves Alembic Pharmaceuticals’ marketing application for its generic version of Eli Lilly’s (NYSE:LLY) type 2 diabetes med Jardiance (empagliflozin), the first generic OK’d in the U.S.
Tentative approval means that Alembic’s marketing application met the requirements for approval, but patent issues need to be resolved before full approval is granted.
LLY is down a fraction after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.